News & Updates
Filter by Specialty:
Combined oral contraceptives and VTE: Which pill conveys the highest risk in young women?
Combined oral contraceptives (COCs) that contain gestodene confer a fivefold increased risk of venous thromboembolism (VTE) in young women as compared with those that contain levonorgestrel and the lowest doses of ethinylestradiol, as shown in a study.
Combined oral contraceptives and VTE: Which pill conveys the highest risk in young women?
29 Aug 2022
Add-on pembrolizumab–tocilizumab combo reduces hospitalization period in severe COVID-19
In the treatment of patients with severe COVID-19, adding the combination of pembrolizumab plus tocilizumab to standard of care (SOC) appears to result in higher and faster discharge from the hospital without sequelae, as shown in the proof-of-concept phase II COPERNICO trial.
Add-on pembrolizumab–tocilizumab combo reduces hospitalization period in severe COVID-19
29 Aug 2022
Gout, hyperuricaemia meds less common among diabetics on SGLT2is
Patients with type 2 diabetes mellitus (T2DM) taking sodium-glucose cotransporter 2 inhibitors (SGLT2is) are less likely to be prescribed antigout or antihyperuricaemic drugs, a recent study has found.
Gout, hyperuricaemia meds less common among diabetics on SGLT2is
28 Aug 2022
Dulaglutide safely controls glucose in T2D with CKD
In patients with type 2 diabetes (T2D) with chronic kidney disease (CKD), once-weekly dosage with dulaglutide achieves adequate glycaemic control along with a reduced decline in estimated glomerular filtration rate (eGFR), reports a recent study.
